Tuesday - May 13, 2025
DEERFIELD, Ill. / Dec 06, 2024 / Business Wire / Walgreens Boots Alliance, Inc. (Nasdaq: WBA) will release its fiscal year 2025 first quarter results at 7 a.m. ET on Thursday, January 9, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET.
The conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call.
About Walgreens Boots Alliance
Walgreens Boots Alliance (Nasdaq: WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 175-year heritage of caring for communities.
A trusted, global innovator in retail pharmacy with approximately 12,500 locations across the U.S., Europe and Latin America, WBA plays a critical role in the healthcare ecosystem. Through dispensing medicines, improving access to pharmacy and health services, providing high quality health and beauty products and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare in the thousands of communities it serves and beyond.
WBA employs approximately 312,000 people, with a presence in eight countries and consumer brands including: Walgreens, Boots, Duane Reade, No7 Beauty Company and Benavides. The Company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. In fiscal 2024, WBA scored 100% on the Disability Equality Index for disability inclusion.
More Company information is available at www.walgreensbootsalliance.com.
Last Trade: | US$11.43 |
Daily Change: | 0.21 1.87 |
Daily Volume: | 17,275,205 |
Market Cap: | US$9.880B |
March 06, 2025 January 10, 2025 December 13, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load